Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients

Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients

S-CKD602 is a PEGylated liposomal formulation of CKD-602, a potent topoisomerase I inhibitor. The objective of this study was to characterize the bidirectional pharmacokinetic–pharmacodynamic (PK–PD) interaction between S-CKD602 and monocytes. Plasma concentrations of encapsulated CKD-602 and monocy...

Full description

Bibliographic Details
Main Authors: Wu, Huali, Ramanathan, Ramesh K, Zamboni, Beth A, Strychor, Sandra, Ramalingam, Suresh, Edwards, Robert P, Friedland, David M, Stoller, Ronald G, Belani, Chandra P, Maruca, Lauren J, Bang, Yung-Jue, Zamboni, William C
Format: Online
Language:English
Published: Dove Medical Press 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480239/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480239/

Similar Items